Ney Carter Borges: Additive Cardiovascular Risk Reduction Through Dual Targeting of Lipoprotein(a) and Interleukin-6 Signalling
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Additive Cardiovascular Risk Reduction Through Dual Targeting of Lipoprotein(a) and Interleukin-6 Signalling: A Translational Genetic Insight
The persistent burden of cardiovascular disease (CVD), despite advances in lipid-lowering and preventive therapies, underscores the importance of residual risk pathways – particularly lipoprotein(a) [Lp(a)] and systemic inflammation.
This study elegantly bridges these two domains by leveraging Mendelian randomization to simulate lifelong exposure to reduced Lp(a) levels and attenuated interleukin-6 (IL-6) signalling, offering a quasi-causal perspective on their individual and combined effects.
Analyzing data from over 408,000 individuals in the UK Biobank, the investigators demonstrate that genetically lower Lp(a) is consistently associated with a significant reduction in multiple cardiovascular outcomes, including coronary heart disease (CHD), stroke, heart failure, and peripheral arterial disease.
Importantly, this protective effect remains stable regardless of the underlying inflammatory milieu, suggesting that Lp(a)-mediated risk operates through both inflammatory and non-inflammatory mechanisms.
In parallel, reduced IL-6 signalling – representing a more proximal and biologically relevant inflammatory axis than hsCRP – was independently associated with lower risks of CHD, atrial fibrillation, and aortic aneurysm.
The most compelling finding, however, emerges from the factorial analysis: the combination of lower Lp(a) and reduced IL-6 signalling produced a markedly greater reduction in CHD risk (OR ~0.25), consistent with an additive, rather than synergistic, effect .
This nuanced distinction is clinically meaningful.
It implies that these pathways contribute independently to atherogenesis and that dual targeting may address complementary mechanisms – lipid-driven plaque formation and inflammation-driven plaque instability.
Observational analyses further reinforce this concept, showing the lowest event rates among individuals with both low Lp(a) and low IL-6 levels.
From a translational standpoint, these findings anticipate a future paradigm in which combined therapies—such as RNA-based Lp(a) inhibitors alongside anti–IL-6 agents—may redefine residual risk management.
Yet, caution is warranted: genetic proxies reflect lifelong exposure, and ongoing randomized trials will be critical to confirm the magnitude and timing of benefit in clinical practice.
In essence, this study shifts the conversation from ‘which pathway matters most’ to ‘how multiple pathways can be strategically integrated’ to achieve deeper cardiovascular protection.”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference
-
Oct 19, 2026, 10:27Heather M. Johnson: Join the Discussion on Optimizing the CTEPH Diagnostic Pathway
-
Oct 19, 2026, 10:18Flora Peyvandi: Unravelling the Complexity of VWF Through Genetics
-
Oct 19, 2026, 09:55High DOAC Adherence in Patients With Ischemic Stroke and AF – International Journal of Stroke